Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
We developed click editors, comprising HUH endonucleases, DNA-dependent DNA polymerases and CRISPR–Cas9 nickases, which together enable programmable precision genome engineering from simple DNA templates.
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Indapta Therapeutics is using a subset of natural killer cells found in healthy donors to supercharge monoclonal antibodies to fight cancer and autoimmune disease.
Errors in the US Patent and Trademark Office’s automated program to calculate patent expiration dates could result in hundreds of millions of dollars in added costs to drug prices.
The NIH Applicant Assistance Program represents a new paradigm guiding the design of meaningful policy interventions for increasing equity of participation in scientific grant funding.